TWiV 1002: Clinical update with Dr. Daniel Griffin

In his weekly clinical update, Dr. Griffin discusses completeness and spin of medRxiv preprints and associated published abstracts of COVID-19 randomized clinical trials, lessons learned from a COVID-19 dog screening pilot in California K-12 schools, SARS-CoV-2 reinfection and severity of the disease, effectiveness of COVID-19 bivalent vaccine, Molnupiravir and risk of post-acute sequelae of COVID-19, risk of new-onset long Covid following reinfection with SARS-CoV-2, low vitamin D levels associated with long COVID syndrome in COVID-19 survivors, and clinical experience with the α2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in “Long-COVID19”. Click arrow to play Download TWiV 1002 (27 MB .mp3, 44 min) Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Completeness and spin of medRxiv preprint and published abstracts of COVID-19 randomized clinical trials (JAMA) Lessons learned from a COVID-19 dog screening pilot (JAMA) SARS-CoV-2 reinfection and severity of the disease (Viruses) Effectiveness of COVID-19 bivalent vaccine (medRxiv) Molnupiravir and risk of post-acute sequelae of COVID-19 (BMJ) Risk of new-onset long Covid following reinfection with SARS-CoV-2 (medRxiv) Low vitamin D levels are associated with Long COVID in COVID-19 survivors (JCEM) Clinical experience with the α2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for treatment of Long-COVID19 (NIH) Contribute to our ASTMH fundraiser at PWB Letters read on TWiV 1002 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]